#868: Tim’s Founder Kitchen — From Brainstorm to The President’s Office in Two Months (Featuring Jake Becraft, Strand Therapeutics)
Jake Becraft is the CEO and co-founder of Strand Therapeutics, a company building one of the most advanced programmable genetic medicine platforms in biotechnology. Under his leadership, Strand is redefining what RNA medicines can do by enabling cell-selective targeting and therapeutic payload delivery inside the body, unlocking a new class of precision genetic therapies.
This episode is brought to you by:
- Helix Sleep premium mattresses: HelixSleep.com/Tim (20% off any purchase)
- Incogni,which automatically removes your personal data from the web, helping shield you from fraud, scams, and identity theft: Incogni.com/Tim (use code TIM at checkout and get 60% off an annual plan)
Timestamps:
- [00:00:00] Start.
- [00:06:07] What Strand does.
- [00:08:19] The Boston dinner.
- [00:11:05] The image of a body riddled with cancer.
- [00:15:05] What stuck for the muggles in the pitch deck.
- [00:17:14] A good drug vs. a good product.
- [00:19:40] Tricking cancer into snitching on itself.
- [00:27:38] The abscopal effect.
- [00:34:04] Potency, specificity, and delivery.
- [00:35:46] First principles thinking.
- [00:36:38] The precipice of a revolution.
- [00:41:14] The thousand people in the room.
- [00:48:38] Psychedelic medicine as a cautionary tale.
- [00:51:17] What actually catches a policymaker’s attention.
- [00:53:42] Breakthrough vs. incremental.
- [00:54:55] What’s in it for the policymakers?
- [00:58:08] The 80/20 wish list.
- [01:01:31] Australia’s CTN system.
- [01:03:51] Sheep, psychedelics, and red-tape arbitrage.
- [01:05:22] China’s clinical-trial flywheel vs. slow-motion American loss.
- [01:06:53] The bicoastal biotech ethos.
- [01:08:10] Can the FDA actually pull this off?
- [01:12:12] The Sophie’s Choice of pharma development.
- [01:14:16] Lost arts of founder mode.
- [01:15:23] Rockets for tumors, T-cells, and beyond.
- [01:19:16] Viral in policy circles.
- [01:23:09] The Washington Post headline and the PickFu split test.
- [01:27:56] Solution-first storytelling.
- [01:33:54] RNA medicine and platform therapeutics.
- [01:39:17] Moderna’s 62 days.
- [01:40:33] Uber Eats and the de-risked launch.
- [01:44:17] CEO blockers.
- [01:45:52] Where’s biotech’s SpaceX moment?
- [01:46:53] Elon Musk betting black on the wheel.
- [01:51:55] AWS and the post-conviction / pre-consensus window.
- [01:58:47] COVID politicization.
- [01:59:46] Insulin, growth hormone, and the original platform story.
- [02:01:35] Biotech as pharma’s little brother.
- [02:03:29] More recent role models, Apple edition.
- [02:04:50] Art Levinson, Steve Jobs, and the biotech-tech crossover.
- [02:06:25] The iPhone as a delivery platform.
- [02:08:25] Spotify’s problem and the future of bespoke medicine.
- [02:10:07] Baby KJ and the limits of liver-only solutions.
- [02:11:19] Parting thoughts.
*
For show notes and past guests on The Tim Ferriss Show, please visit tim.blog/podcast.
For deals from sponsors of The Tim Ferriss Show, please visit tim.blog/podcast-sponsors
Sign up for Tim’s email newsletter (5-Bullet Friday) at tim.blog/friday.
For transcripts of episodes, go to tim.blog/transcripts.
Discover Tim’s books: tim.blog/books.
Follow Tim:
Twitter: twitter.com/tferriss
Instagram: instagram.com/timferriss
YouTube: youtube.com/timferriss
Facebook: facebook.com/timferriss
LinkedIn: linkedin.com/in/timferriss
See P
